Primary CNS lymphoma: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
|||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*AIDS defining malignancy that is strongly related to [[Epstein-Barr virus]] (EBV) infection | *[[AIDS]]-defining malignancy that is strongly related to [[Epstein-Barr virus]] (EBV) infection | ||
*Occurs with profound immunosuppression (CD4 counts <50cells/uL) | *Occurs with profound immunosuppression (CD4 counts <50cells/uL) | ||
* Accounts for approximately 20 to 30% of CNS lesions in patients with AIDs | * Accounts for approximately 20 to 30% of CNS lesions in patients with AIDs | ||
| Line 16: | Line 16: | ||
**Lesions that involve the corpus callosum, periventricular, or periependymal areas are more likely to be due to a lymphoma<ref>Forsyth PA. Biology and management of AIDS-associated primary CNS lymphomas. Hematol Oncol Clin North Am. 1996;10(5):1125-34.</ref> | **Lesions that involve the corpus callosum, periventricular, or periependymal areas are more likely to be due to a lymphoma<ref>Forsyth PA. Biology and management of AIDS-associated primary CNS lymphomas. Hematol Oncol Clin North Am. 1996;10(5):1125-34.</ref> | ||
**Solitary lesions are often large (>4cm)<ref>Thurnher MM. CNS involvement in AIDS: spectrum of CT and MR findings. Eur Radiol. 1997;7(7):1091-7.</ref> | **Solitary lesions are often large (>4cm)<ref>Thurnher MM. CNS involvement in AIDS: spectrum of CT and MR findings. Eur Radiol. 1997;7(7):1091-7.</ref> | ||
*Lumbar puncture: | *[[Lumbar puncture]]: | ||
**CSF cytology | **CSF cytology | ||
**CSF EBV PCR | **CSF EBV PCR | ||
| Line 23: | Line 23: | ||
==Management== | ==Management== | ||
*High-dose methotrexate therapy (3 g/m<sup>2</sup> for four to eight cycles) | *High-dose [[methotrexate]] therapy (3 g/m<sup>2</sup> for four to eight cycles) | ||
*Steroids | *[[Steroids]] | ||
*Potent antiretroviral therapy | *Potent antiretroviral therapy | ||
*Radiation therapy | *Radiation therapy | ||
Revision as of 16:28, 17 May 2017
Background
- AIDS-defining malignancy that is strongly related to Epstein-Barr virus (EBV) infection
- Occurs with profound immunosuppression (CD4 counts <50cells/uL)
- Accounts for approximately 20 to 30% of CNS lesions in patients with AIDs
Clinical Features
- Can present with a variety of focal or nonfocal signs and symptoms
- Confusion, lethargy, memory loss, hemiparesis, aphasia, mental status changes, seizures
- Constitutional symptoms (systemic B symptoms)
Differential Diagnosis
HIV associated conditions
- HIV neurologic complications
- HIV pulmonary complications
- Ophthalmologic complications
- Other
- HAART medication side effects[1]
- HAART-induced lactic acidosis
- Neuropyschiatric effects
- Hepatic toxicity
- Renal toxicity
- Steven-Johnson's
- Cytopenias
- GI symptoms
- Endocrine abnormalities
Evaluation
- CT scan: well-defined focal lesion, isodense or hyperdense to the gray matter
- MRI scan (higher diagnostic yield): variable, isointense or hypointense lesions on T1-weighted images
- Lumbar puncture:
- CSF cytology
- CSF EBV PCR
- Should also obtain toxoplasma serologies, most are treated empirically for toxoplasma while serology is pending
- Stereotactic brain biopsy if necessary
Management
- High-dose methotrexate therapy (3 g/m2 for four to eight cycles)
- Steroids
- Potent antiretroviral therapy
- Radiation therapy
Disposition
See Also
External Links
References
- ↑ Gutteridge, David L MD, MPH, Egan, Daniel J. MD. The HIV-Infected Adult Patient in The Emergency Department: The Changing Landscape of the Disease. Emergency Medicine Practice: An Evidence-Based Approach to Emergency Medicine. Vol 18, Num 2. Feb 2016.
- ↑ Forsyth PA. Biology and management of AIDS-associated primary CNS lymphomas. Hematol Oncol Clin North Am. 1996;10(5):1125-34.
- ↑ Thurnher MM. CNS involvement in AIDS: spectrum of CT and MR findings. Eur Radiol. 1997;7(7):1091-7.